1. Home
  2. CPRX vs SUPN Comparison

CPRX vs SUPN Comparison

Compare CPRX & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.28

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$46.08

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPRX
SUPN
Founded
2002
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.0B
IPO Year
2006
2010

Fundamental Metrics

Financial Performance
Metric
CPRX
SUPN
Price
$31.28
$46.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$35.00
$61.60
AVG Volume (30 Days)
2.9M
678.4K
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
28.24
N/A
EPS
0.50
N/A
Revenue
$119,072,803.00
$392,755,000.00
Revenue This Year
$9.20
$22.70
Revenue Next Year
$10.51
$19.14
P/E Ratio
$62.58
N/A
Revenue Growth
16.39
N/A
52 Week Low
$19.05
$31.16
52 Week High
$32.56
$59.68

Technical Indicators

Market Signals
Indicator
CPRX
SUPN
Relative Strength Index (RSI) 72.86 37.60
Support Level $31.00 $43.67
Resistance Level $31.33 $46.89
Average True Range (ATR) 0.08 1.69
MACD -0.19 -0.34
Stochastic Oscillator 81.94 5.43

Price Performance

Historical Comparison
CPRX
SUPN

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: